Universidad del País Vasco/Euskal Herriko Unibertsitatea-ko ikertzaileekin lankidetzan egindako argitalpenak (28)

2024

  1. BEST-CLI International Collaborative: planning a better future for patients with chronic limb-threatening ischaemia globally

    British Journal of Surgery, Vol. 111, Núm. 2

  2. EJVES Vascular Forum Moves Forward

    EJVES Vascular Forum

2023

  1. Ceftaroline and Avibactam Removal by Continuous Renal Replacement Therapies: An in vitro Study

    Blood Purification, Vol. 52, Núm. 5, pp. 464-473

  2. ESVS Podcasts: Connecting with the World

    EJVES Vascular Forum

2022

  1. Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study

    Journal of Intensive Care, Vol. 10, Núm. 1

  2. Three-dimensional printing as a cutting-edge, versatile and personalizable vascular stent manufacturing procedure: Toward tailor-made medical devices

    International Journal of Bioprinting, Vol. 9, Núm. 2, pp. 219-255

2021

  1. Population pharmacokinetics of levetiracetam and dosing evaluation in critically ill patients with normal or augmented renal function

    Pharmaceutics, Vol. 13, Núm. 10

  2. Página web de casos clinicorradiológicos para la enseñanza de la radiología

    FEM. Revista de la Fundación Educación Médica, Vol. 24, Núm. 1, pp. 51-53

  3. Quantification of ceftaroline in human plasma using high‐performance liquid chromatography with ultraviolet detection: Application to pharmacokinetic studies

    Pharmaceutics, Vol. 13, Núm. 7

2020

  1. Impact of augmented renal clearance on the pharmacokinetics of linezolid: Advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspective

    International Journal of Infectious Diseases, Vol. 93, pp. 329-338

  2. Novel population pharmacokinetic model for linezolid in critically ill patients and evaluation of the adequacy of the current dosing recommendation

    Pharmaceutics, Vol. 12, Núm. 1

2019

  1. Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment

    Journal of Critical Care, Vol. 50, pp. 69-76

2018

  1. Population pharmacokinetics of daptomycin in critically ill patients

    International Journal of Antimicrobial Agents, Vol. 52, Núm. 2, pp. 158-165

2017

  1. RNAseq based transcriptomics study of SMCs from carotid atherosclerotic plaque: BMP2 and IDs proteins are crucial regulators of plaque stability

    Scientific Reports, Vol. 7, Núm. 1

2016

  1. Standard and fenestrated endograft sizing in EVAR planning: Description and validation of a semi-automated 3D software

    Computerized Medical Imaging and Graphics, Vol. 50, pp. 9-23

2015

  1. Optimizing the dosing regimen of linezolid in critically ill septic patients undergoing continuous hemodiafiltration using a pharmacokinetic/pharmacodynamic analysis and Monte Carlo simulation

    Intensive Care Medicine Experimental

  2. Pharmacokinetic/pharmacodynamic analysis of linezolid in critically ill patients with severe sepsis treated with renal replacement therapy

    Intensive Care Medicine Experimental

2014

  1. Caffeine: Forms of consumption, toxicity, therapeutic effects and their use in medicine

    Caffeine: Consumption, Side Effects and Impact on Performance and Mood (Nova Science Publishers, Inc.), pp. 35-88

  2. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: Application to pharmacokinetic/pharmacodynamic analysis

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 1, pp. 180-189

2008

  1. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy

    Clinical Pharmacokinetics, Vol. 47, Núm. 3, pp. 173-180